Interferon Gamma Suppresses Collagen-Induced Arthritis by Regulation of Th17 through the Induction of Indoleamine-2,3-Deoxygenase

Jaeseon Lee*, Jennifer Lee*, Mi-Kyung Park, Mi-Ae Lim, Eun-Mi Park, Eun-kyung Kim, Eun-Ji Yang, Seon-Yeong Lee, Joo-Yeon Jhun, Sung-Hwan Park, Ho-Youn Kim, Mi-La Cho*

The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, South Korea

Abstract

CS7BL/6 mice are known to be resistant to the development of collagen-induced arthritis (CIA). However, they show a severe arthritic phenotype when the Ifng gene is deleted. Although it has been proposed that IFN-γ suppresses inflammation in CIA via suppressing Th17 which is involved in the pathogenesis of CIA, the exact molecular mechanism of the Th17 regulation by IFN-γ is poorly understood. This study was conducted to 1) clarify that arthritogenic condition of IFN-γ knockout (KO) mice is dependent on the disinhibition of Th17 and 2) demonstrate that IFN-γ-induced indoleamine2,3-dioxygenase (IDO) is engaged in the regulation of Th17. The results showed that the IFN-γ KO mice displayed increased levels of IL-17 producing T cells and the exacerbation of arthritis. Also, production of IL-17 by the splenocytes of the IFN-γ KO mice was increased when cultured with type II collagen. When IL17 was deleted from the IFN-γ KO mice, only mild arthritis developed without any progression of the arthritis score. The proportion of CD44<sup>high</sup>CD62L<sup>low</sup> memory-like T cells were elevated in the spleen, draining lymph node and mesenteric lymph node of IFN-γ KO CIA mice. Meanwhile, CD44<sup>high</sup>CD62L<sup>high</sup> naive T cells were increased in IFN-γ and IL-17 double KO CIA mice. When Th17 polarized CD4<sup>+</sup> T cells of IFN-γ KO mice were co-cultured with their own antigen presenting cells (APCs), a greater increase in IL-17 production was observed than in co-culture of the cells from wild type mice. In contrast, when APCs from IFN-γ KO mice were pretreated with IFN-γ, there was a significant reduction in IL-17 in the co-culture system. Of note, pretreatment of 1-methyl-DL-tryptophan, a specific inhibitor of IDO, abolished the inhibitory effects of IFN-γ. Given that IFN-γ is a potent inducer of IDO in APCs, these results suggest that IDO is involved in the regulation of IL-17 by IFN-γ.

Citation: Lee J, Lee J, Park M-K, Lim M-A, Park E-M, et al. (2013) Interferon Gamma Suppresses Collagen-Induced Arthritis by Regulation of Th17 through the Induction of Indoleamine-2,3-Deoxygenase. PLoS ONE 8(4): e60900. doi:10.1371/journal.pone.0060900

Received November 23, 2012; Accepted March 4, 2013; Published April 16, 2013

Introduction

Rheumatoid arthritis (RA) is an autoimmune disease that is characterized by multiple, persistent synovial inflammation that can lead to joint destruction if left untreated. Activated by unidentified autoantigens, T cells are known to play a crucial role in initiating and maintaining the inflammatory process. Collagen-induced arthritis (CIA) model in DBA/1 mice has been widely used as an animal model of RA. In this model, T helper 1 (Th1) immune response was thought to be involved in the pro-inflammatory process. However, the role of IFN-γ, a characteristic Th1 cytokine, was of interest as IFN-γ receptor deficient mice showed rather exacerbated arthritic phenotypes of CIA [1]. This was further supported by the report that C57BL/6 mice, which are known to be resistant to the development of CIA, developed arthritis with severe inflammation when the Ifng gene was deleted [2]. Moreover, the protective effect of IFN-γ is not limited to CIA. It has been reported that a deficiency in IFN-γ may contribute to pro-inflammatory conditions such as experimental autoimmune neuritis [3], experimental autoimmune encephalomyelitis [4], delayed-type hypersensitivity [5], and acute graft-versus-host disease [6].

The inhibitory function of IFN-γ was once suggested to be associated with IL-1β. It was reported that the expression of IL-1β increased and arthritis was ameliorated with anti-IL-1β treatment in IFN-γ deficient C57BL/6 mice [7]. The authors argued that IFN-γ was a negative regulator in the development of autoimmune arthritis in B6 mice and in part was involved with the control of IL-1β production. However, with the emergence of the Th17 cells which are crucial in autoimmune diseases, the protective role of IFN-γ has been explained to be associated with the suppression of Th17 and its effector function. It was reported that IFN-γ could suppress the IL-23-driven Th17 development [8]. And the exacerbated CIA in IFN-γ deficient mice was demonstrated to be due to lack of Th17 inhibition [9]. Nevertheless, very little is known about the exact mechanism of how IFN-γ exerts its inhibitory effect on Th17. It has been proposed that the inhibition of IL-17 by...
IFN-γ is dependent on STAT-1 [10], but there are no details on its mechanism.

Indoleamine 2,3-dioxygenase (IDO) is a catabolic enzyme which mediates tryptophan degradation [11]. It is widely expressed in various cells including tumor cells [12], dendritic cells [13], macrophages [14], microglia [15], eosinophils [16], fibroblasts [17], and endothelial cells [18]. IDO expression is known to be induced by various stimuli including cytokines such as IFN-γ, pathogen-associated molecular patterns and co-stimulatory molecules [19]. In the context of immune cells, the role of IDO is to suppress T cell generation by depriving tryptophan and producing the toxic tryptophan metabolite-kynurenine [20]. Of note, it has been demonstrated to play a crucial role in the suppression of autoimmunity as it regulates autoreactive T cells [21]. Specifically, several studies demonstrated that IDO negatively regulates the Th17 response [22,23]. Therefore, we hypothesized that IDO induced by IFN-γ is involved in the suppression of Th17 in CIA. The present study demonstrated that the suppression of Th17 by IFN-γ was abolished with 1-methyl-DL-tryptophan, a specific inhibitor of IDO.

Materials and Methods

Mice
Male C57BL/6, IFN-γ KO, IDO KO mice (8–10 weeks) were purchased from Jackson laboratory. IL-17 KO mice were obtained from Dr. Y. Iwakura (University of Tokyo, Tokyo, Japan). IFN-γ KO mice were backcrossed to IL-17 KO mice over 10th generations and double KO (DKO) mice were selected for by PCR, which were given standard mouse chow (Ralston Purina) and water ad libitum. All experimental procedures were examined and approved by the Animal Research Ethics Committee of the Catholic University (Seoul, Korea).

Induction and Assessment of Arthritis
The protocol to develop arthritis of the C57BL/6 mice was referred to Jun et al [24]. Briefly, 200 μg/ml chicken type II collagen (CII, Chondrex, Seattle, WA) emulsified with CFA (Arthrogen-CIA, Redmond, WA) (1:1v/v) was injected at the base of tail and in a slightly more anterior site of wild type and IFN-γ KO mice. Three weeks later, a boost mixed with CII (100 μg/ml) emulsified with IFA (Difco, Detroit, MI) (1:1v/v) was given with the same protocol as above. Arthritic score measurements were performed as follows: 0 = no joint swelling; 1 = slight edema and erythema limited to the foot or ankle; 2 = slight edema and erythema from the ankle to the tarsal bone; 3 = moderate edema and erythema from the ankle to the tarsal bone; and 4 = edema and erythema extending from the ankle to the entire leg, with severe swelling of the wrist or ankle. The final arthritis score was calculated as the sum of scores from all four legs, which were assessed by three independent observers with no knowledge of the experimental groups.

Preparation of Cell Suspension
Spleens were removed from IFN-γ KO or IFN-γ and IL-17 DKO mice 5 weeks after primary immunization. Spleen tissue was minced. Splenic red blood cells were removed with an ACK lysis buffer (2.66% Tris, pH 7.65, and 0.83% NH4Cl). Cell suspension was passed through a 40 μm strainer (BD Falcon, Bedford, MA) and re-suspended with 5% fetal bovine serum (Gibco, Grand Island, NY) containing RPMI1640 (Gibco) media.

CD4+ T cell Isolation and Stimulation
Spleen cells were washed with 0.5% bovine serum albumin (BSA, Sigma, St Louis, MO), 5 mM ethylenediaminetetraacetic acid (EDTA, Sigma) containing PBS buffer (pH 7.2). After centrifugation at 1300 rpm and 4°C, cells were incubated with CD1-coated magnetic beads (MiltenyiBiotec, Bergisch Gladbach, Germany) and isolated on MACS separation columns (Miltenyi-Biotec). Positively selected CD4+ T cells were stimulated with plate-bound 0.5 μg/ml of anti-CD3 mAbs (BD biosciences, San Jose, CA), soluble 1 μg/ml of anti-CD28 mAbs (BD biosciences), 2 μg/ml of anti-IFN-γ Abs (R&D systems, Minneapolis, MN), 2 μg/ml of anti-IL-4 Abs (R&D systems), 2 ng/ml of recombinant TGF-β (R&D systems), 20 ng/ml of recombinant IL-6 (R&D systems) for 3 days for Th17 polarization. Negatively selected non-CD4 cells were regarded as antigen presenting cells (APCs) and stimulated with 100 ng/ml of recombinant IFN-γ for 3 days with or without pretreatment with 100 μM of 1-methyl-DL-tryptophan (Sigma) for 2 hours. In co-cultures using Th17 polarized cell and APCs, both cells were harvested, washed and concentrated with 5x105 cells/well in a 24-well plate. APCs were irradiated at 3000 rad before the co-culture. Each culture supernatant was collected and used for cytokine ELISA.

Histology
Mouse joint tissue was fixed in 4% paraformaldehyde, decalcified, EDTA-embedded and embedded in paraffin. The sections (7 μm) were stained with hematoxylin and eosin, Safranin O, and toluidine blue to detect proteoglycans. For immunohistochemistry, mouse joint or spleen tissue sections were blocked with 1% normal goat serum followed by staining with antibodies to IL-17 (1 μg/ml, SantaCruz, CA, USA), RANKL (200 ng/ml, SantaCruz), RANK (200 ng/ml, SantaCruz), IL-2 (100 ng/ml, SantaCruz), IL-15 (200 ng/ml, SantaCruz), IL-21 (200 ng/ml, SantaCruz), and isotype control antibody (1 μg/ml, SantaCruz). The sections were then incubated with the appropriate biotinylated secondary antibodies (SantaCruz) and followed by an avidin–enzyme complex. PBS containing 0.05% Tween 20 was used for washing after each step. Chromogenic reactions were visualized with 3,3′-diaminobenzidine (Sigma), and the nuclei were counterstained with hematoxylin. Slides were mounted in permanent mounting media (Dako, Glostrup, Denmark).

Mixed Lymphocyte Culture
Splenocytes (2x105 cells/well) were plated on 96-well-flat-bottomed plate in 200 μl/well. They were stimulated with CII 20 μg/ml or anti-CD3 0.5 μg/ml for 4 days followed by the incorporation of 1 μCi/ml [3H]-thymidine (GE Healthcare, Piscataway, NJ) for the last 18 hours of the indicated total culture interval. Then the radioactivity was measured with a Micro Beta (Pharmacia Biotech, Piscataway, NJ).

Analysis of Anti-CII IgG Antibody
Blood samples collected from the mice were assayed using mouse IgG/IgG1 ELISA quantification kit (Bethyl lab, Montgomery, TX). Briefly, CII (4 μg/ml) was coated in PBS at 4°C overnight. Levels of IgG1 and IgG2a were measured in mice sera diluted 1000-fold, according to the manufacturer’s instruction.

Quantitative RT-PCR
Messenger RNA was isolated using Trizol (Invitrogen, Grand Island, USA) according to the manufacturer’s instructions. Total RNA (2 μg) was reverse transcribed at 10 min for 25°C, 30 min for 55°C and finally 5 min for 85°C using Transcriptor First
Strand cDNA Synthesis kit (Roche, Mannheim, Germany). Real-time PCR amplification was performed with 0.3–0.5 μl reverse transcription product in a LightCycler 1.5 (Roche) by using FastStart Universal SYBR Green Master (Roche) according to the manufacturer’s guidelines. The following sense and antisense primers for each molecule were used for IFN-γ KO, IFN-α/β, IL-17, IL-21, and IL-2: 5′-GGGTCAACCTCCAGTGTTTCA-3′ (sense) and 5′-TAAAATGCAAGTGATTTTG-3′ (antisense); β-actin, 5′-GAATCGTGCTGACATCAAAG-3′ (sense) and 5′-GTAGTTTCATGGATGCCACAG-3′ (antisense). The PCR cycling conditions were as follows: 0 min at 95°C, 45 cycles of 15 s at 95°C, 45 s at 60°C, and 20 s at 72°C. To verify that equivalent amounts of RNA were added to each PCR reaction, PCR amplification of the murine β-actin was performed for each sample. Relative fold induction was calculated using the equation 2^−ΔΔCp, where ΔΔCp is ΔCp(stimulated)−ΔCp(control) and ΔCp is Cp(stimulated)−Cp(β-actin) and Cp is the cycle at which the threshold is crossed. PCR product quality was monitored using post-PCR melting curve analysis. Flowcytometry Single cell suspensions of spleen were washed with FACS buffer (0.5% BSA, 0.02% sodium azide in PBS, pH 7.4) and stained with following antibodies: APC conjugated anti CD44 antibody, PE conjugated anti CD62L antibody (BD biosciences), PerCP conjugated anti CD4 antibody (eBioscience). For intracellular FACS staining, cells were fixed with Cytotox/cytoperme solution (BD, San Diego, CA), and the data were analyzed with FlowJo software, version 7.6 (TreeStar, Ashland, OR). The lymphocyte group was gated on the whole cell region by the forward/side scatter properties, CD4+ region was gated on lymphocyte followed by fluorescence only for the analysis of naive/memory T cell population. Detection of IFN-17 by ELISA Antibodies directed against mouse IL-17 and biotinylated anti-mouse IL-17 Abs (R&D Systems) were used as the capture and detection Abs, respectively. The fluorescent substrate HRP-avidin (R&D Systems) was used for color development. The amounts of mouse IL-17 Abs (R&D Systems) were used as the capture and production by IFN-γ KO mice (Figure 1f). IL-17 producing cells were also more intensely infiltrated in the joints of CIA induced IFN-γ KO mice (Figure 1e). As well, there was an increased cell proliferation in response to CII and anti CD3 antibody stimulation in IFN-γ KO mice when compared to the WT b6 KO mice (CIA nil: 975±4.2; CIA CII: 1350±14.1, CIA aCD3: 56292±1023.9; CIA IFN-γ KO nil: 941±177.5, CIA IFN-γ KO CII: 2481±473.8, CIA (IFN-γ KO) aCD3: 69423±3438.0; CPM) (Figure 1f). CIA-specific IL-17 production was observed only in the splenocytes from IFN-γ KO mice (CIA nil: 12.9±6.4 pg/ml, CIA CII: 11.0±4.0 pg/ml, CIA (IFN-γ KO): 9.3±0.3 pg/ml, CIA (IFN-γ KO): 23.6±2.0 pg/ml (Figure 1g). IFN-γ and IL-17 Double Knockout Mice did not Develop Progressive Arthritis To demonstrate that IL-17 was the major cytokine that lead to the exacerbation of arthritis in IFN-γ deficient mice, CIA was induced in IFN-γ IL-17 DKO mice. Until 10 weeks after immunization, only mild CIA without progression (Arthritis score 5) was developed in DKO mice while IFN-γ KO mice exhibited severe joint swelling (Figure 2a). In addition, the level of anti CII IgG, IgG1 measured in the sera obtained at 5 weeks post-immunization was significantly lower in DKO mice (anti CII IgG, CIA/IFN-γ KO): 0.208±0.018, CIA/IFN-17 DKO: 0.086±0.008; anti CII IgG1, CIA/IFN-γ KO: 0.308±0.027, CIA/IFN-γ IL-17 DKO: 0.112±0.060; anti CII IgG2a, CIA/IFN-γ KO: 0.109±0.037, CIA/IFN-γ IL-17 DKO: 0.056±0.001 O.D.(450 nm) (Figure 2b). Mice were sacrificed at 10 weeks post-immunization to evaluate the histology of the joints. Joint destruction was not observed in the joints of DKO mice (Histology score, CIA/IFN-γ KO: 3.67±0.289, CIA/IFN-γ IL-17 DKO: 0.67±0.289; Cartilage score, CIA/IFN-γ KO: 3.50±0.500, CIA/IFN-γ IL-17 DKO: 1.00±0.500 (Figure 2c)). RANK and RANKL expression in the synovium was also addressed as RANK-RANKL interaction has been known to be essential in the differentiation of osteoclast which plays the key role in bone destruction in CIA. As expected, the expression of RANKL, RANK was low in the synovium of CIA-induced DKO mice (Figure 2d). Collectively, these data suggest that IL-17 is critical in collagen-specific inflammation in IFN-γ KO mice. Memory Type CD4+ T cells were Decreased in IFN-γ IL-17 DKO CIA Mice It can be easily deduced that the population of antigen specific memory T cell is decreased in DKO mice as severe arthritis is not developed in DKO mice. Indeed, the proportion of memory type CD44hiCD62Lhi CD4+ T cells were decreased in DKO mice. On the contrary, the proportion of naive CD4+ T cells significantly increased in DKO mice compared to WT mice at 5 weeks post-immunization (Figure 3a, 3b). To further explain the altered subpopulation of CD4+ T cells, the expression of the cytokines associated with T cell proliferation and memory cell development such as IL-2, IL-15 and IL-21 in the joint synovium was investigated. While IL-2 and IL-15 expression was observed in both models, there was a significant reduction in IL-15 expression within the synovium of CIA-induced DKO mice (Figure 3c).
Figure 1. IFN-γ deficient mice demonstrated increased IL-17 production and severe phenotype of collagen-induced arthritis (CIA). Splenocytes from WT B6 or IFN-γ KO B6 mice were cultured with media alone and with 0.5 μg/ml of plate bound anti CD3 monoclonal antibodies for 48 hrs (a) to 72 hrs (b) and stained with PE conjugated anti-IL-17 antibody. The proportion of IL-17 producing cells was measured using flow cytometry. (c) Splenocytes from WT B6 or IFN-γ KO B6 mice were cultured in a Th17 polarizing condition. The mRNA expression of IL-17 and the protein level of IL-17 in the supernatant were measured. (d) Sections from the hind paws of WT B6 with or without CIA and IFN-γ KO B6 with or without CIA were obtained at 9th week after primary CII+CFA immunization. Joint tissue sections were stained with Hematoxylin and Eosin, Toluidine Blue, Safranin O. Infiltration of immune cells in joint synovium between tibia and tarsal bone was observed using microscope and scored according to the referred standard. (e) IL-17 was significantly high in CIA (IFN-γ KO). Joint sections were fixed with paraffin to perform Immunohistochemistry.
Suppression of IL-17 by IFN-γ is Associated with IDO

CD4+ T cells isolated from WT B6 and IFN-γ KO B6 were cultured in Th17 polarizing conditions. Non-CD4+ cells were cultured with media only or 100 ng/ml of recombinant IFN-γ. Th17 polarized cells and non-CD4+ cells/non-CD4+IFN-γ cells were then co-cultured in a ratio of 1:1. The expression of IL-17 in the co-culture supernatant was significantly low when Th17 polarized cells were co-cultured with IFN-γ treated non-CD4 cells (Figure 4a). Therefore, we hypothesized a certain molecule which was induced by IFN-γ in non CD4+ cells suppressed the production of IL-17 of CD4+ T cells. IDO was one of the candidate molecules as it was induced by IFN-γ [25] in non CD4+ cells and known to be associated with Treg [26–29] which suppresses Th17. Pretreatment of 1-MT partially restored the production of IL-17 suppressed by IFN-γ (Figure 4b). Furthermore, CD4+ T cells isolated from IDO KO mice produced more IL-17 than those from WT B6 mice when cultured in Th17 polarizing conditions(Figure 4c, mRNA fold increase, B6:1.0, IDO−/−: 6.75±0.14). Next it was investigated whether IFN-γ-induced IDO exerted the same inhibitory effects in spontaneous arthritis model IL-1Ra KO mice. As expected, IL-17 production from the splenocytes of IL-1Ra KO mice decreased after IFN-γ treatment and the inhibitory effect was abolished with pretreatment with 1-MT, as in IFN-γ KO mice (Figure 4d).

Discussion

IFN-γ is a characteristic Th1 cytokine which was believed to play a pro-inflammatory role in autoimmune arthritis model in the past. However, recent evidence has suggested that the net effect of IFN-γ is rather associated with amelioration of arthritis [30]. Indeed, Lemmel et al. showed that low dose IFN-γ treatment had therapeutic potential in human RA, although the authors did not suggest the underlying mechanism [31]. Consistent with these findings, our study demonstrated that CIA is exacerbated in IFN-γ KO mice. IFN-γ has been reported to exert anti-inflammatory effects by various mechanisms including the suppression of differentiating monocyte/macrophages in osteoclasts, which are...
Crucial in the bone erosion process of arthritis [32]. IFN-γ also inhibits IL-1β-mediated production of MMP-1 and MMP-3 by synovial fibroblast in the early phase of arthritis [33]. Moreover, it has been reported that IFN-γ is able to facilitate regulatory T cell development [34], and most importantly inhibit the development of Th17 cells and suppress IL-17 which is a key participant in autoimmune diseases [35].

There have been several studies that investigated the contribution of IL-17 to CIA exacerbation in IFN-γ KO mice, where IL-17 neutralizing antibodies were used for blockade [36]. Kelchtermans...
et al. showed the amelioration of arthritis with the treatment of the IL-17 neutralizing antibody in IFN-γ KO C57BL/6 mice [10]. They also demonstrated that the level of anti CII IgG2a was significantly reduced after treatment with the IL-17 antibody. In the present study, IFN-γ and IL-17 DKO mice were used to illustrate that the proinflammatory condition driven by IFN-γ deletion largely depends on the function of IL-17. As expected, DKO mice were not susceptible to CIA, which was confirmed by comparing clinical arthritis scores, as well as histologic arthritis scores between the IFN-γ KO mice and the IFN-γ IL-17 DKO mice. The production of IgG, IgG1, IgG2a subtypes of type II collagen specific antibodies were also reduced in DKO mice. This seemed to be due to the lack of IL-17-driven antibody production.

During the investigation of evaluating the proportion of the T cell subtype in IFN-γ KO mice and IFN-γ IL-17 DKO mice, results showed a decrease in the proportion of CD4+CD62Llow memory-like T cells in double KO mice. In contrast, CD4+CD62Lhigh naive T cells were less frequently observed in IFN-γ KO mice. These findings were similar to the findings of Yang et al. which showed decreased proportion of memory T cells in IL-2 and STAT3 double KO mice, demonstrating the requirement of STAT3 in IL-2 deficiency-driven inflammatory conditions [37]. It is plausible to assume that in IFN-γ KO mice, naïve T cells are activated and differentiate into effector cells, which result in synovial inflammation, whereas DKO mice display suppression in inflammation where a larger proportion of naïve cells remain inactivated. Furthermore, the expression of IL-15, an important cytokine in maintaining memory T cells was diminished within the synovial tissue of the DKO mice. This seemed to have contributed to the decrease of the memory cell proportion. Further investigation is required to interpret the exact meaning of the decreased memory-like CD4+ T cells in DKO mice.

The precise molecular mechanism of IFN-γ in the suppression of IL-17 is yet to be elucidated. We sought a molecule that was induced by IFN-γ and known to inhibit IL-17: Indoleamine 2,3deoxygenase (IDO). It has been reported in several studies that IDO negatively regulates Th17 response in CIA models. Chen et al. demonstrated that CIA was ameliorated by IDO gene
therapy through synovial IL-17 reduction and CD4+ cell apoptosis [22]. Criaud et al. also reported that IDO deficient mice showed exacerbation of CIA with increased infiltration of Th17 cells in the inflammatory joints [23]. In our study, when the splenocytes of IFN-γ KO mice were treated with IFN-γ and IL-17, the level of IL-17 was partially recovered compared to the untreated cells treated with IFN-γ alone. This was further supported by the experiments performed using IL-1Ra KO mice. When Th17 polarized cells were co-cultured with IFN-γ pretreated APCs from IFN-γ KO mice, the level of IL-17 in the supernatant was decreased compared to the co-culture with non IFN-γ pretreated APCs. This suggests that there may be a partial effect from the material secreted by the APCs, which was induced by IFN-γ. These findings suggest that enhancing IDO activity by IFN-γ treatment would be a promising therapeutic strategy in the treatment of RA. Although Schroecksnadel et al. [38] reported that IDO activity was already enhanced in the patients with RA, it seems that immunosuppressive activity of increased IDO is only partially able to suppress disease activity, and further stimulation of the enzyme can contribute to treatment.

However, the inhibitory function of IFN-γ could not be entirely explained by the action of IDO. In contrary to our expectations, IDO expression was not reduced in the IFN-γ KO mice (data not shown) even before CIA was induced. This may be due to the expression of IDO being induced by various stimuli other than IFN-γ. Moreover, IDO expression in the supernatant of co-culture of T cells and IFN-γ treated APCs was not assessed. Future studies are required to elucidate whether the level of IDO increases with IFN-γ treatment.

Conclusion

We observed the exacerbation of CIA in IFN-γ KO C57BL/6 mice, confirming the protective role of IFN-γ in the development of CIA. This was abrogated in IFN-γ and IL-17 DKO mice, indicating that IFN-γ negatively regulates CIA by suppressing IL-17 function. The inhibitory function of IFN-γ on IL-17 production was abolished with IDO inhibitor, 1-MT, suggesting that IDO was involved in the inhibitory mechanism of IFN-γ.

Author Contributions

Conceived and designed the experiments: JSI, JL, MKP, MLC. Performed the experiments: JSI, MKP, MAL, EMP, EKK, EJY, SYL, JYJ. Analyzed the data: JSI, JL, MKP, MLC. Contributed reagents/materials/analysis tools: SHYP. Wrote the paper: JSI, JL, MLC.

References

1. Mansury-Schwartz B, Chiochico G, Bessis N, Abelsizia-Amar O, Batteux F, et al. (1997) High susceptibility to collagen-induced arthritis in mice lacking IFN-γ gene. J Immunol 158: 5301–5306.
2. Chu CQ, Song Z, Mayton L, Wu B, Wooley PH (2003) IFN-γamma deficient C57Bl/6 (H-2b) mice develop collagen induced arthritis with predominant usage of T cell receptor Vβ8 and Vβ2 in arthritic joints. Ann Rheum Dis 62: 983–990.
3. Zhang HL, Azimullah S, Zheng XY, Wang XK, Amir N, et al. (2012) IFN-γamma deficiency exacerbates experimental autoimmune neuritis in mice despite a mitigated systemic Th1 immune response. J Neuroimmunol 246: 10–28.
4. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, D’Arcois C, et al. (1996) Mice with a disrupted IFN-γamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 156: 5–7.
5. Wang S, Fan Y, Brumman RC, Yang X (1999) IFN-gamma knockout mice show reduced inflammation and improved survival during local challenge. Eur J Immunol 29: 3782–3792.
6. Murphy WJ, Welnaik LA, Taub DD, Wiltrout RH, Taylor PA, et al. (1998) Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 102: 1742–1748.
7. Guedez YB, Whittington KB, Clayton JL, Joosten LA, van de Loo FA, et al. (2001) Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum 44: 2413–2424.
8. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, et al. (2005) Interleukin-17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1132–1139.
9. Chu CQ, Swift D, Alocn D, Tocker J, Elkon KB (2007) Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 56: 1145–1151.
10. Kelchtermans H, Schurgers E, Gebes E, Milera T, Van Damme J, et al. (2009) Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counter-regulation by interferon-gamma. Arthritis Res Ther 11: R122.
11. Moller AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4: 762–774.
12. Munn DH, Moller AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147–1154.
13. Moller AL, Baban B, Chandler P, Marshall B, Jhaever K, et al. (2003) Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 171: 1652–1655.
14. Munn DH, Shafizadeh E, Atwood JT, Bondarev I, Pashine A, et al. (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189: 1363–1372.
15. Yadav MC, Burudi EM, Alirezaei M, Flynn CC, Watry DD, et al. (2007) IFN-γamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia 55: 1383–1396.
16. Odemuyiwa SO, Gahary A, Li Y, Pattangula L, Lee JE, et al. (2004) Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J Immunol 173: 5909–5913.
17. Park MK, Oh HJ, Heo YM, Park E-M, Cho M-L, et al. (2011) Myeloid differentiation primary response protein 86 blockade upregulates indoleamine 2,3-dioxygenase expression in rheumatoid synovial fibroblasts. Experimental and Molecular Medicine 43: 446.
18. Beutelspacher SC, Tan PH, McClure MO, Larkin DF, Lechler RI, et al. (2006) Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of allografts. Am J Transplant 6: 1350–1359.
19. Munn DH (2006) Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 18: 220–225.
20. Munn DH, Sharma MD, Baban B, Harding HF, Zhang Y, et al. (2005) GCN2 kinase in T cells mediates proliferative arrest and energy induction in response to indoleamine 2,3-dioxygenase. Immunity 22: 633–642.
21. Curi A, Trabelleni S, Salvestrini V, Baccarini M, Lemoli RM (2009) The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematologic. Blood 115: 2904–2901.
22. Chen SY, Wu CL, Lai MD, Lin CC, Yo YT, et al. (2011) Amelioration of rat collagen-induced arthritis through CD4+ T cells apoptosis and synovial interleukin-17 reduction by indoleamine 2,3-dioxygenase gene therapy. Hum Gene Ther 22: 145–154.
23. Criaud G, Simleyte E, Inglis J, Essex D, Williams RO (2009) Indoleamine 2,3-dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis. Arthritis Rheum 60: 1342–1351.
24. Inglis J, Simleyte E, McCann FE, Criaud G, Williams RO (2008) Protocol for the induction of arthritis in C57BL/6 mice. Nat Protoc 3: 612–618.
25. Chen W (2011) IDO: more than an enzyme. Nat Immunol 12: 809–811.
26. Ikemoto T, Shimada M, Komatsu M, Yamada S, Saito Y, et al. (2013) Indoleamine 2,3-dioxygenase Affects the Aggressiveness of Intraductal Papillary Mucinous Neoplasms Through Forks3/CD4+CD25+ T Cells in Peripheral Blood. Pancreas 42: 130–134.
27. Sun J, Yu J, Li H, Yang L, Wei F, et al. (2011) Upregulated expression of indoleamine 2,3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells. J Exp Clin Cancer Res 30: 82.
28. Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, et al. (2012) IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18: 6110–6121.
29. Yan Y, Zhang GX, Gran B, Fallarino F, Yu S, et al. (2010) IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol 185: 5953–5961.
30. Schurgers E, Billiau A, Mathys P (2011) Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon-gamma. J Interferon Cytokine Res 31: 917–926.
31. Lemmel EM, Brackertz D, Franke M, Gaus W, Hardt PW, et al. (1998) Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int 8: 87–93.
32. Takahashi N, Mundy GR, Roodman GD (1986) Recombinant human interferon-gamma inhibits formation of human osteoclast-like cells. J Immunol 137: 3544–3549.

33. Page CE, Smale S, Carty SM, Amos N, Lauder SN, et al. (2010) Interferon-gamma inhibits interleukin-1beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Res Ther 12: R49.

34. Wang Z, Heng J, Sun W, Xu G, Li N, et al. (2006) Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest 116: 2434–2441.

35. Sarkar S, Cooney LA, White P, Dunlop DB, Endres J, et al. (2009) Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gamma and IL-4. Arthritis Res Ther 11: R158.

36. Irmler IM, Gajda M, Brauer R (2007) Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol 179: 6228–6236.

37. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, et al. (2011) Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12: 247–254.

38. Schroocksnadel K, Winkler G, Dufner C, Wirleitner B, Schirmer M, et al. (2006) Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol 25: 354–357.